Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 24

1.

Characterization of Major and Clinically Relevant Non-Major Bleeds in the APEX Trial.

Yee MK, Gibson CM, Nafee T, Kerneis M, Daaboul Y, Korjian S, Chi G, AlKhalfan F, Hernandez AF, Hull RD, Cohen AT, Goldhaber SZ.

TH Open. 2019 Apr 17;3(2):e103-e108. doi: 10.1055/s-0039-1685496. eCollection 2019 Apr.

2.

Rates of Chronic Medical Conditions in 1991 Gulf War Veterans Compared to the General Population.

Zundel CG, Krengel MH, Heeren T, Yee MK, Grasso CM, Janulewicz Lloyd PA, Coughlin SS, Sullivan K.

Int J Environ Res Public Health. 2019 Mar 16;16(6). pii: E949. doi: 10.3390/ijerph16060949.

3.

Most Promising Therapies in Interventional Cardiology.

Kerneis M, Nafee T, Yee MK, Kazmi HA, Datta S, Zeitouni M, Afzal MK, Jafarizade M, Walia SS, Qamar I, Pitliya A, Kalayci A, Al Khalfan F, Gibson CM.

Curr Cardiol Rep. 2019 Mar 13;21(4):26. doi: 10.1007/s11886-019-1108-x. Review.

PMID:
30868280
4.

Implantable Cardiac Alert System for Early Recognition of ST-Segment Elevation Myocardial Infarction.

Gibson CM, Holmes D, Mikdadi G, Presser D, Wohns D, Yee MK, Kaplan A, Ciuffo A, Eberly AL 3rd, Iteld B, Krucoff MW.

J Am Coll Cardiol. 2019 Apr 23;73(15):1919-1927. doi: 10.1016/j.jacc.2019.01.014. Epub 2019 Mar 3.

PMID:
30842028
5.

Reduction of Cardiovascular Mortality and Ischemic Events in Acute Medically Ill Patients.

Nafee T, Gibson CM, Yee MK, Kerneis M, Daaboul Y, Korjian S, Chi G, Kalayci A, Afzal MK, Kazmi H, Datta S, AlKhalfan F, Hernandez AF, Hull RD, Harrington RA, Cohen AT, Goldhaber SZ.

Circulation. 2019 Feb 26;139(9):1234-1236. doi: 10.1161/CIRCULATIONAHA.118.038654. No abstract available.

PMID:
30802169
6.

Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention.

Kerneis M, Yee MK, Mehran R, Nafee T, Bode C, Halperin JL, Peterson ED, Verheugt FWA, Wildgoose P, van Eickels M, Lip GYH, Cohen M, Fox KAA, Gibson CM.

Circ Cardiovasc Interv. 2019 Feb;12(2):e007124. doi: 10.1161/CIRCINTERVENTIONS.118.007124.

PMID:
30704287
7.

The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction.

Gibson CM, Kerneis M, Yee MK, Daaboul Y, Korjian S, Mehr AP, Tricoci P, Alexander JH, Kastelein JJP, Mehran R, Bode C, Lewis BS, Mehta R, Duffy D, Feaster J, Halabi M, Angiolillo DJ, Duerschmied D, Ophuis TO, Merkely B.

Am Heart J. 2019 Feb;208:81-90. doi: 10.1016/j.ahj.2018.11.008. Epub 2018 Nov 22.

PMID:
30580130
8.

Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial.

Kalayci A, Gibson CM, Chi G, Yee MK, Korjian S, Datta S, Nafee T, Gurin M, Haroian N, Qamar I, Hull RD, Hernandez AF, Cohen AT, Harrington RA, Goldhaber SZ.

Thromb Haemost. 2018 Dec;118(12):2046-2052. doi: 10.1055/s-0038-1675606. Epub 2018 Nov 12.

PMID:
30419597
9.

Betrixaban for first-line venous thromboembolism prevention in acute medically ill patients with risk factors for venous thromboembolism.

Nafee T, Gibson CM, Yee MK, Alkhalfan F, Chi G, Travis R, Mir M, Kalayci A, Jafarizade M, Ganti A, Kazmi SH, Ghaffarpasand E, Pitliya A, Datta S, Sharfaei S, Alihashemi M, Elsaiey A, Qamar I, Jahansouz M, Talib U, Kahe F, Habibi S, Abdelwahed M, Tariq F, Kaur M, Younes A, Walia SS, Singh A, Dildar SM, Afzal MK, Kerneis M.

Expert Rev Cardiovasc Ther. 2018 Nov;16(11):845-855. doi: 10.1080/14779072.2018.1534068. Epub 2018 Oct 15. Review.

PMID:
30296387
10.

D-Dimer Levels and Effect of Rivaroxaban on Those Levels and Outcomes in Patients With Acute Coronary Syndrome (An ATLAS ACS-TIMI 46 Trial Substudy).

AlKhalfan F, Kerneis M, Nafee T, Yee MK, Chi G, Plotnikov A, Braunwald E, Gibson CM.

Am J Cardiol. 2018 Nov 1;122(9):1459-1464. doi: 10.1016/j.amjcard.2018.07.032. Epub 2018 Aug 4.

PMID:
30217378
11.

SECURE PCI: how important can a subgroup analysis be?

Kerneis M, Yee MK, Gibson CM.

J Thorac Dis. 2018 Jun;10(Suppl 17):S2032-S2034. doi: 10.21037/jtd.2018.05.155. No abstract available.

12.

Fatal or Irreversible Bleeding and Ischemic Events With Rivaroxaban in Acute Coronary Syndrome.

Gibson CM, Levitan B, Gibson WJ, Yee MK, Murphy SA, Yuan Z, Chakrabarti AK, Lee M, Braunwald E.

J Am Coll Cardiol. 2018 Jul 10;72(2):129-136. doi: 10.1016/j.jacc.2018.04.055.

13.

Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention.

Chi G, Yee MK, Kalayci A, Kerneis M, AlKhalfan F, Mehran R, Bode C, Halperin JL, Verheugt FWA, Wildgoose P, van Eickels M, Lip GYH, Cohen M, Peterson ED, Fox KAA, Gibson CM.

J Thromb Thrombolysis. 2018 Oct;46(3):346-350. doi: 10.1007/s11239-018-1703-5.

PMID:
29943350
14.

Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients.

Gibson CM, Nafee T, Yee MK, Chi G, Korjian S, Daaboul Y, AlKhalfan F, Kerneis M, Goldhaber SZ, Hull R, Hernandez AF, Cohen AT, Harrington RA.

Am Heart J. 2018 Apr;198:84-90. doi: 10.1016/j.ahj.2017.12.015. Epub 2017 Dec 27.

PMID:
29653652
15.

Meta-analysis of self-reported health symptoms in 1990-1991 Gulf War and Gulf War-era veterans.

Maule AL, Janulewicz PA, Sullivan KA, Krengel MH, Yee MK, McClean M, White RF.

BMJ Open. 2018 Feb 13;8(2):e016086. doi: 10.1136/bmjopen-2017-016086.

16.

Association of D-dimer Levels with Clinical Event Rates and the Efficacy of Betrixaban versus Enoxaparin in the APEX Trial.

Gibson CM, Jennings LK, Chi G, Yee MK, Halaby R, Nafee T, AlKhalfan F, Kerneis M, Korjian S, Daaboul Y, Goldhaber SZ, Hull RD, Hernandez AF, Cohen AT, Harrington RA.

TH Open. 2018 Jan 8;2(1):e16-e24. doi: 10.1055/s-0037-1615288. eCollection 2018 Jan.

17.

Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial).

Chi G, Yee MK, Amin AN, Goldhaber SZ, Hernandez AF, Hull RD, Cohen AT, Harrington RA, Gibson CM.

Circulation. 2018 Jan 2;137(1):91-94. doi: 10.1161/CIRCULATIONAHA.117.031187. No abstract available.

PMID:
29279341
18.

Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial.

Yee MK, Nafee T, Daaboul Y, Korjian S, AlKhalfan F, Kerneis M, Wiest C, Goldhaber SZ, Hernandez AF, Hull RD, Cohen AT, Harrington RA, Gibson CM.

J Thromb Thrombolysis. 2018 Jan;45(1):1-8. doi: 10.1007/s11239-017-1583-0.

PMID:
29188425
19.

Competing risk analysis in a large cardiovascular clinical trial: An APEX substudy.

Arbetter DF, Jain P, Yee MK, Michalak N, Hernandez AF, Hull RD, Goldhaber SZ, Harrington RA, Gold A, Cohen AT, Gibson CM.

Pharm Stat. 2017 Nov;16(6):445-450. doi: 10.1002/pst.1823. Epub 2017 Aug 24.

PMID:
28840662
20.

Multiple Mild Traumatic Brain Injuries Are Associated with Increased Rates of Health Symptoms and Gulf War Illness in a Cohort of 1990-1991 Gulf War Veterans.

Yee MK, Janulewicz PA, Seichepine DR, Sullivan KA, Proctor SP, Krengel MH.

Brain Sci. 2017 Jul 9;7(7). pii: E79. doi: 10.3390/brainsci7070079.

Supplemental Content

Loading ...
Support Center